CP 99994

Drug Profile

CP 99994

Latest Information Update: 04 Aug 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Developer Schering-Plough
  • Class
  • Mechanism of Action Neurokinin 1 antagonists; Substance P inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cough
  • Discontinued Allergic rhinitis; Arrhythmias; Asthma; Nausea and vomiting; Pain; Rheumatic disorders

Most Recent Events

  • 04 Aug 2009 No development reported - Preclinical for Cough in USA (IV)
  • 21 Jun 2004 Data presented at the 100th International Conference of the American Thoracic Society (ATS-2004) have been added to the Respiratory Tract Disorders pharmacodynamics section
  • 06 Apr 2004 Preclinical trials in Cough in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top